@article{24436f15c789445d856596b505e8f767,
title = "How much do periventricular lesions assist in distinguishing migraine with aura from CIS?",
abstract = "Objective To evaluate in clinically isolated syndrome (CIS) and migraine with aura (MA) how the number of periventricular lesions (PVLs) detected at MRI influences diagnostic performance when the Magnetic Resonance Imaging in Multiple Sclerosis (MAGNIMS) or the 2017 revised criteria are applied. Methods In this retrospective study, white matter hyperintensities (WMH) of 84 patients with MA and 79 patients with CIS were assessed using manual segmentation technique. Lesion probability maps (LPMs) and voxel-wise analysis of lesion distribution by diagnosis were obtained. Furthermore, we performed a logistic regression analysis based on lesion locations and volumes. Results Compared to patients with MA, patients with CIS showed a significant overall higher T2WMH mean number and volume (17.9 ± 16.9 vs 6.2 ± 11.9 and 3.1 ± 4.2 vs 0.3 ± 0.6 mL; p < 0.0001) and a significantly higher T2 WMH mean number in infratentorial, periventricular, and juxtacortical areas (p < 0.0001). LPMs identified the periventricular regions as the sites with the highest probability of detecting T2 WMH in patients with CIS. Voxel-wise analysis of lesion distribution by diagnosis revealed a statistically significant association exclusively between the diagnosis of CIS and the PVLs. MAGNIMS criteria demonstrated the highest specificity in differentiating patients with CIS from patients with MA (100% vs 87%) against a predictable lower sensitivity (63% vs 72%). Conclusions PVLs play a key role in the differential diagnosis between MA and CIS, particularly when there are more than 3. Future studies on multiple sclerosis criteria might reconsider the 3 PVLs to minimize the risk of misdiagnosis.",
author = "Caterina Lapucci and Laura Saitta and Giulia Bommarito and Sormani, {Maria Pia} and Matteo Pardini and Laura Bonzano and Mancardi, {Giovanni Luigi} and Claudio Gasperini and Antonio Giorgio and Matilde Inglese and {De Stefano}, Nicola and Luca Roccatagliata",
note = "Funding Information: C. Lapucci received honoraria for travel expenses for attending meetings from Genzyme and Roche. L. Saitta and G. Bommarito report no disclosures relevant to the manuscript. M. Sormani received consulting fees from Biogen Idec, Merck Serono, Teva, Genzyme, Roche, Novartis, GeNeuro, and Medday. M. Pardini received research support from Novartis and personal fees from Teva and Merck. L. Bonzano reports no disclosures relevant to the manuscript. G. Mancardi received honoraria for lecturing, travel expenses for attending meetings, and financial support for research from Bayer Schering, Biogen Idec, Sanofi-Aventis, Merck Serono Pharmaceuticals, Novartis, Genzyme, and Teva. C. Gasperini received compensation for consulting services and/or speaking activities from Teva, Merck, Genzyme, Biogen, Bayer, and Roche. A. Giorgio reports no disclosures relevant to the manuscript. M. Inglese received research grants from NIH, DOD, NMSS, FISM, and Teva Neuroscience. N. De Stefano is a consultant for Schering, Biogen-Idec, Teva, Novartis, Sanofi-Genzyme, Roche, and Merck-Serono; has grants or grants pending from FISM and Novartis; is on the speakers bureaus of Biogen-Idec, Teva, Novartis, Sanofi-Genzyme, Roche, and Merck-Serono; and has received travel funds from Teva, Novartis, Sanofi-Genzyme, Roche, and Merck Serono. L. Roccatagliata reports no disclosures relevant to the manuscript. Go to Neurology.org/N for full disclosures. Publisher Copyright: Copyright {\textcopyright} 2019 American Academy of Neurology.",
year = "2019",
doi = "10.1212/WNL.0000000000007266",
language = "English",
volume = "92",
pages = "1--6",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins Ltd.",
number = "15",
}